Amgen, Inc. vs Paycom Software Inc — how do they compare? Amgen, Inc. trades at $412.21 (market cap $224.14B), while Paycom Software Inc trades at $211 (market cap $9.57B). The key difference: Amgen, Inc. is far larger — about 23.4× Paycom Software Inc's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | PAYC | |
|---|---|---|
Market Cap | $224.14B | $9.57B |
Sector | Health | Technology |
52-Week High | $417.20 | $233.89 |
52-Week Low | $271.18 | $113.59 |
Enterprise Value | $267.45B | $10.35B |
Dividend Yield | 2.43% | 0.71% |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →